Archynetys Live news trend intelligence
◼ Archived Business 🔮 Archynetys predicts: fades by tomorrow — graded ✗ wrong

Compass says depression drug has long-lasting benefits

Compass Pathways reports long-lasting benefits from its psilocybin depression treatment following a second Phase 3 trial.

By · Published July 9, 2026 at 10:42 UTC · Updated July 9, 2026 at 22:32 UTC

5sources
5articles
3velocity
+0%since first seen
57d agofirst detected

Evidence dossier

Intelligence passport

54/100 Publishable
5distinct sources shown
40velocity measurements
1language editions checked
All brief claims passed the second-source checkbrief evidence status

Measured timeline

  1. Detected The first matching coverage entered the Archynetys cluster.
  2. Latest coverage observed Most recent article currently attached to this story cluster.
  3. Peak measured velocity The recorded velocity reached 3.
  4. Evidence threshold reached The story had enough independent coverage for an explanatory brief.
  5. Outcome review added Archynetys revisited the signal after coverage cooled.

Source diversity sample: Business Wire · Moomoo · Psychedelic Alpha · Endpoints News · STAT.

How this dossier is built: methodology · AI policy · corrections.

📍 How it ended

Compass Pathways announced six-month data from a second Phase 3 trial confirming a rapid and durable profile for its depression treatment. The company touted these long-lasting benefits ahead of a year-end filing.

A launch is being eyed for the first half of 2027.

Epilogue added 55d ago, after coverage quieted.

Coverage (5)

The brief

Compass Pathways has released six-month data from its second Phase 3 trial (COMP006). The company states that the data confirms a rapid and durable profile for its depression drug, leading to an increase in company shares.

Coverage from STAT, Endpoints News, and Business Wire emphasizes the durability of the drug's benefits. Psychedelic Alpha and Moomoo highlight the positive late-stage trial results and the subsequent market reaction.

According to coverage, the company is planning a year-end filing and targeting a launch in the first half of 2027.

Synthesized by Archynetys from the headlines below under a strict no-invention contract. ✓ fact-checked: all claims supported by sources Updated 56d ago.

Quick answers

What trial data was recently released?

Compass Pathways announced six-month data from its second Phase 3 trial, known as COMP006.

What is the nature of the drug being tested?

The drug is a psilocybin-based treatment for depression.

When is the treatment expected to launch?

Coverage indicates a target launch in H1 2027.

The coverage curve

How fast coverage is spreading — measured hourly from article rate × source diversity. How this works →

Topics

Compass Pathways Psilocybin Phase 3 Trial Depression Treatment

Related trends

Open prediction lab

Can you beat the machine?

Pick tomorrow's top trend, then compare your result with Archynetys's self-graded forecast.

Make a prediction →